trans-4-Dimethylaminocrotonic Acid Hydrochloride CAS 848133-35-7 Maʻemaʻe >98.0% (HPLC) Afatinib Dimaleate Intermediate

ʻO ka wehewehe pōkole:

trans-4-Dimethylaminocrotonic Acid Hydrochloride

CAS: 848133-35-7

Maʻemaʻe: >98.0% (HPLC)

'Ano: Keokeo a aneane keokeo ka pauda

Waena o Afatinib Dimaleate (CAS: 850140-73-7)

Hoʻokaʻaʻike: Kauka Alvin Huang

Mobile/Wechat/WhatsApp: +86-15026746401

E-Mail: alvin@ruifuchem.com


Huahana Huahana

Nā Huahana Pili

Huahana Huahana

wehewehe:

Na Waiwai Kemika:

Inoa Kimia trans-4-Dimethylaminocrotonic Acid Hydrochloride
Nā huaʻōlelo like trans 4-Dimethylaminocrotonic Acid HCl;(E)-4-(Dimethylamino)-2-Butenoic Acid Hydrochloride;(E)-4-Dimethylaminocrotonic Acid Hydrochloride;(2E) -4- (Dimethylamino) aka-2-Enoic Acid Hydrochloride;Afatinib int-2
Helu CAS 848133-35-7
Kūlana Kūʻai Ma ka Waihona, Ka Uuna Kūʻai
ʻĀpana Molekala C6H12ClNO2
Kaumaha Molecular 165.62
ʻO ka ʻike Hygroscopic.ʻAiʻoniʻoni
Lae hehee 160.0 a 164.0 ℃
Ka hikiwawe DMSO (Lihi), Methanol (Lihi), Wai (Lihi)
COA & MSDS Loaʻa
Ke kumu Shanghai, Kina
Brand Kemika Ruifu

Nā kikoʻī:

'ikamu Nā kikoʻī
Ka nana aku Keokeo a aneane keokeo pauda
Maʻemaʻe / Kaʻina Hanana >98.0% (HPLC)
Maʻemaʻe / Kaʻina Hanana >98.0% (NMR)
Māmā (KF) <0.50%
Koena ma ka Ignition <0.20%
Hoʻokahi haumia <0.50%
Nā Metala Kaumaha (e like me Pb) <20ppm
Infrared Spectrum Kūlike i ka hoʻolālā
1 H NMR Spectrum Proton NMR Spectrum
Kūlana hoʻāʻo Kūlana ʻoihana
Hoʻohana Ka waena o Afatinib, Afatinib Dimaleate

Pūʻolo a me ka waiho ʻana:

Pūʻolo:ʻO ka ʻōmole, ʻeke ʻeke alumini, 25kg / pahu pahu pahu, a i ʻole e like me ka makemake o ka mea kūʻai aku.

Kūlana mālama:E mālama i loko o nā pahu i hoʻopaʻa ʻia ma kahi maloʻo a maloʻo;E pale i ka malamalama a me ka wai.

Hoʻouna:Hāʻawi i ka honua ma ka lewa, e FedEx / DHL Express.Hāʻawi wikiwiki a hilinaʻi hoʻi.

Maʻemaʻe Chromatographic:

Mea hana: Agilent 1200 HPLC HPLC chromatograph, DAD detector.
Kona: Agilent XDB-C18,250*4.6mm, 5μm
Māhele Mobile: B: 1.95g sodium octane sulfonate + 8ml phosphoric acid + 5ml triethylamine + 500ml wai
C: acetonitrile
Ka hoʻomākaukau ʻana i ka māhele kelepona hui ʻia: e lawe i ka solution 400ml B a me 100ml acetonitrile, hui maikaʻi a like, a paʻi i ka wai i hoʻokahi pae.
Kahe kahe: 0.5ml/min54bar
Ka wela o ke kolamu: 25 ℃
Loʻihi nalu: 210nm
Laʻana hoʻonā: ua hoʻohana ʻia ka pae kelepona e like me ka solvent, ka laʻana paʻa: 0.0040g/2ml, ka nui o ka laʻana 2.0μl.

Pono:

1

FAQ:

www.ruifuchem.com

Noi:

ʻO ka trans-4-Dimethylaminocrotonic Acid Hydrochloride (CAS: 848133-35-7) kahi reagent i hoʻohana ʻia i ka hoʻomākaukau ʻana i ka tyrosine kinase e kāohi ana i nā mea antitumor.Hiki ke hoʻohana ʻia ka trans-4-Dimethylaminocrotonic Acid Hydrochloride ma ke ʻano he waena o Afatinib (CAS: 439081-18-2), Afatinib Dimaleate (CAS: 850140-73-7), Neratinib (CAS: 698387-09-6).He lāʻau lapaʻau ʻo Afatinib i ʻae ʻia no ka mālama ʻana i ka maʻi maʻi maʻi maʻi ʻole liʻiliʻi liʻiliʻi (NSCLC), i hoʻomohala ʻia e Boehringer Ingelheim.Hana ia ma ke ʻano he angiokinase inhibitor.E like me Lapatinib a me Neratinib, ʻo Afatinib he tyrosine kinase inhibitor (TKI) e pale ʻole i ka epidermal growth factor receptor 2 (Her2) a me ka epidermal growth factor receptor (EGFR) kinases.ʻAʻole ikaika wale ʻo Afatinib i ka EGFRnā hoʻololi i manaʻo ʻia e nā TKI o ka hanauna mua likeerlotinib a i ʻole gefitinib, akā kūʻē pū kekahi i ka poʻe ʻike ʻole i kēia mau lāʻau lapaʻau maʻamau.Ma muli o kāna hana hou aku e kūʻē iā Her2, ke noiʻi ʻia nei no ka maʻi maʻi umauma a me nā maʻi maʻi maʻi EGFR a me Her2 ʻē aʻe.ʻO Neratinib i hoʻomohala ʻia e ka hui ʻo US Wyeth he mea hiki ʻole ke hoʻololi i ka epidermal growth factor receptor (EGFR) inhibitor.He wahi pahuhopu nui ia o nā mole liʻiliʻi tyrosine kinase inhibitors i HER 2 a me HER1 ma hope o Lapatinib, a he mea hiki ole ke hoʻololi i ka ErbB receptor tyrosine kinase inhibitor.Hiki i ka Neratinib ke kaohi i ka HER-1 a me HER-2 o ka ʻohana EGFR (ʻo IC50 he 92 nmol/L a me 59 nmol/L, kēlā me kēia).Ua hōʻike ʻia ka noiʻi haukaʻi ua hoʻohana ʻo Neratinib i ka hopena therapeutic koʻikoʻi ma luna o ka maʻi maʻi ʻaʻai liʻiliʻi liʻiliʻi, ka maʻi ʻaʻai colon, a me ka maʻi maʻi umauma.Ua hōʻike ka phaseⅡclinical trial ua hōʻike ʻo Neratinib i ka maikaʻi a me ka hoʻomanawanui ʻana i nā maʻi maʻi HER-2 maikaʻi me ka maʻi maʻi umauma kiʻekiʻe i loaʻa a ʻaʻole i mālama ʻia ʻo Trastuzumab.Ua hoʻopau ʻia ka pae Ⅲ ka hoʻāʻo ʻana i ka maʻi maʻi umauma ma Kepakemapa 2014.

E kākau i kāu leka ma aneʻi a hoʻouna mai iā mākou